Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2010

View Archived Issues

AstraZeneca reports results from Q4 2009 and the year's R&D highlights

Alnylam initiates phase IIb trial of ALN-RSV01 in RSV-infected lung transplant patients

Curemark's CM-AT autism treatment obtains FDA fast track status

DNA prime/rAd5 boost vaccine regimen safe and immunogenic in HIV

Dual-acting NMDA antagonist neuroprotective in rat model of spinal cord injury

EnzymeRx provides clinical update on pegsitacase

Dual PI3K/mTOR inhibitor with potent preclinical antitumor activity enters phase I trial

Merck T-type calcium channel antagonists effective in models of CNS disorders

Novel HSP90 inhibitors identified by sanofi-aventis

Ranbaxy Laboratories discloses new antibacterial agents

Avexa discovers HIV integrase inhibitors for AIDS therapy

FDA approves once-daily Mirapex ER for early Parkinson's disease

PPARdelta agonists discovered at sanofi-aventis

Ceragenix and BexPharm enter into agreement for EpiCeram

Viamet and Novartis partner for metalloenzyme inhibitors

Hematopoietic prostaglandin-D2 synthase inhibitors claimed by Pfizer for asthma therapy

BioSante reports phase III LibiGel safety data

Concert Pharmaceuticals describes new GABA(A) receptor inverse agonists

GSK and FDA present safety update on Avandia for type 2 diabetes

Takeda and Affymax begin phase III trial of Hematide in chronic renal failure

FDA grants marketing approval for Gilead's Cayston for CF patients with P. aeruginosa

Amylin and Takeda to begin phase III trial of pramlintide/metreleptin in obesity

Lilly, Merck and Pfizer form Asian Cancer Research Group

Additional agents included in strategic collaboration of ExonHit and Allergan

Cyto Pulse obtains Swedish approval for phase I HIV/DNA vaccine trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026